Thank you for the update "Kids' wear is not child's play" (Marketing, June 19) on the happenings at OshKosh B'Gosh. I especially appreciate the insight into the new management's strategies for satisfying its stockholders--moving more production to the Far East. As OshKosh is abandoning the U.S. workforce, I think it would only be just if U.S. buyers abandon the management and stockholders of OshKosh. I'll do my part--and also suggest same to others.
Carey argues that the research budgets for the National Institutes of Health, National Science Foundation, and similar science entities are bloated and should be slashed in the name of efficiency. Carey's analysis is inaccurate because he concentrates only on immediate costs without attending to outcomes of expenditures.
Rather than squandering money, research has yielded new products that accounted for sales of approximately $7.7 billion in 1994 and have actually reduced the cost of medical care. Advances derived from NIH research in general are estimated to save $69 billion in medical costs each year. At a time when the public is greatly concerned with unmet health threats such as effective cancer prevention and treatment and when we are presented with new health threats such as AIDS and Ebola virus, can we really afford to downsize American science?